Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
Jul 09
KALV Share Price Performance
US$13.41
0.35 (2.68%)
Price US$13.41
Share PriceUS$13.41
KALV Community Narratives
There are no narratives available yet.
KalVista Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Apr 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -3.64
- Gross Margin
- 0%
- Net Profit Margin
- 0%
- Debt/Equity Ratio
- 111.0%
KalVista Pharmaceuticals, Inc. Competitors
Snowflake Analysis
About KALV
- Founded
- n/a
- Employees
- 270
- CEO
- WebsiteView website
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.
Market Insight
Market sentiment on BTC treasury companies is moving, and with volatility rising, disagreements over their future prospects are as heated as ever.
Continue reading
U.S. Market Performance
- 7 Days: 0.5%
- 3 Months: 11.8%
- 1 Year: 15.7%
- Year to Date: 10.0%
In the last week, the market has been flat. As for the longer term, the market has risen 16% in the past 12 months. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›